Insider buying last 90 days
No open-market insider purchases were filed for NVCR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NVCR insider filing, plotted on the chart in Gekko.Open NVCR in Gekko
NASDAQ: NVCR
NovoCure (NVCR) Stock Analysis & Forecast
Oct 12 close
$14.72+0.14 (+1.0%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on NovoCure's Optune Pax device, which received approval from Japan's Ministry of Health, Labour and Welfare for locally advanced pancreatic cancer, expanding the addressable patient pool for its Tumor Treating Fields technology. Despite the positive regulatory development, shares fell 4.51 percent following the announcement. Separate coverage noted insiders sold $3.3 million worth of stock, and other pieces compared NovoCure against peers on profitability and analyst recommendations without new company-specific catalysts.
NVCR closes at $14.72, up 1% on the day, sitting between its 50-day average of $16.50 and 200-day average of $14.77, reflecting a mixed trend. The stock's six-month return stands at 37.3%, though the one-month and three-month returns are negative at -5.1% and -5.3% respectively. The GekkoIndex reads 68.9, placing NVCR in the Accumulation zone, with a 5-point change of 1.9. The price sits 27.9% below Gekko Fair Value of $20.41.
NovoCure reports earnings on 29 October 2026, before the open, 17 days away and inside a typical 20-trading-day holding window; the prior reaction to results was -8.8%. Seasonality over the next 20 trading days has averaged -4.6% across 5 years, rising in just 1 of those years. Smart money, insider, and options activity show no data in their respective windows. Analyst consensus among 3 firms includes 2 buy and 1 hold ratings, with a consensus target of $26.86, implying 82.5% consensus upside.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
NovoCure price vs fair value
Close $14.72200-day averageGekko Fair Value $20.41
NovoCure quick facts
- Market cap
- $1.71B
- P/E ratio
- —
- Forward P/E
- 909.1
- EPS, TTM
- −$1.30
- Revenue, TTM
- $699.2M
- Profit margin
- -21.2%
- Dividend yield
- —
- Beta
- 0.99
- Volume
- 781,976 avg 1.34M
- 1-year return
- +2.7%
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±11.9%
- 50-day average
- $16.50
- 200-day average
- $14.77
- Next earnings
- Oct 29 before open
- Shares outstanding
- 116.4M
NovoCure swing-trade checklist
NovoCure scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $14.72 sits between the 50-day ($16.50) and 200-day ($14.77) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.9, Accumulation
Reading 68.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
27.9% below
Price is 27.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 17 days
Reports on Oct 29, 2026, 17 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.6% on average
From this point in the calendar, the next 20 trading days averaged −4.6% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
NovoCure stock chart and price history
NovoCure closed at $14.72 on Oct 12, 2026, +2.7% over the past year, inside a 52-week range of $9.82 to $21.45.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.1%
- 3 months
- −5.3%
- 6 months
- +37.3%
- 1 year
- +2.7%
The full NVCR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NVCR in Gekko
Follow NovoCure through every session
Put NVCR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NVCR in GekkoFree for 7 days. No credit card required.
NovoCure GekkoIndex: the smart money zone
NovoCure’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.9, in the Accumulation zone, up 1.9 points over five sessions.
68.9Accumulation
Up 1.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | +1.5% | +5.8% | ||
| Accumulation (current zone) | 249 | +0.9% | +7.5% | ||
| Neutral | 343 | −0.2% | −1.1% | ||
| Distribution | 31 | +4.1% | +0.5% | ||
| Selling | 7 | Too few readings yet | |||
Average NVCR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the NVCR price, zone by zone.Track NVCR in Gekko
Is NovoCure stock overvalued? Gekko Fair Value
NovoCure trades 27.9% below Gekko Fair Value of $20.41, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what NovoCure shares are worth, recalculated every trading day.
$20.41
Gekko Fair Value, Oct 10, 2026
27.9% Undervalued
At the end of Aug 2026 the price was 24.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NVCR in Gekko
NovoCure insider and Congress trading
No open-market insider purchases were filed for NovoCure, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NVCR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NVCR, plotted on the chart in Gekko.Open NVCR in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold NVCR.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
NovoCure earnings: next date and track record
NovoCure reports on Oct 29, 2026, before the open (17 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 17 days away
- EPS estimate
- −$0.23
- Revenue estimate
- $182.3M
7 of 8reports beat the EPS estimate
±7.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 26, 2026 AI summary
- What they said
- NovoCure's Q4 and Full Year 2025 earnings call highlighted record net revenue of $655M for 2025 (8% YoY growth) and Q4 revenue of $174M. Management emphasized commercial momentum driven by ex-U.S. markets (Germany, France, Japan) and active patient growth. Key developments included FDA approval of Optune Pax for locally advanced pancreatic cancer, PMA submissions for brain metastases, product enhancements, and clinical readouts expected in 2026 (PANOVA-4, TRIDENT). Management provided 2026 net revenue guidance (constant FX) of $675M–$705M (3%–8% growth), expecting Optune Gio growth in low to mid-single digits and non-GBM product contributions of $15M–$25M. Management aims for adjusted EBITDA breakeven in 2026 and plans to reuse existing sales force for the Optune Pax launch, relying on established teams and modest marketing spend. The company resolved a temporary Medicare billing revocation, with billing privileges reinstated and no expected revenue impact. Key risks discussed included reimbursement timing and payer coverage lags for new indications, slow initial Optune Lua uptake, and market maturation leading to stabilized growth.
- Guidance
- Annual net revenue guidance (constant FX) of $675 million to $705 million for 2026, implying 3%–8% YoY growth. Assumptions: Optune Gio net revenue growth in the low to mid-single digits; contributions from non-GBM products (Optune Lua and Optune Pax) of $15M–$25M; modest contributions from new markets (Spain, Czechia, British Columbia); potential adjusted EBITDA breakeven as a possibility in 2026. No specific EBITDA or margin numeric guidance beyond breakeven possibility.
- Risks flagged
- Reimbursement and payer coverage timing for new indications (Optune Pax and Optune Lua), potential lag between active patients and revenue recognition during launch period, previous slow uptake of Optune Lua in U.S. and Germany leading to rightsizing marketing spend, market maturation leading to lower growth rates, and any administrative/regulatory issues like the Medicare billing revalidation (though resolved).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 26, 2026 | −$0.22 est −$0.41 | $174.4M est $174.4M | −8.8% |
| Oct 30, 2025 | −$0.33 est −$0.42 | $167.2M est $174.4M | −5.0% |
| Jun 5, 2025 | −$0.31 est −$0.46 | $158.8M est $158.8M | +1.7% |
| Feb 27, 2025 | −$0.61 est −$0.36 | $161.3M est $147.6M | −13.2% |
| Oct 30, 2024 | −$0.28 est −$0.33 | $155.1M est $153.0M | −10.1% |
| Jul 25, 2024 | −$0.31 est −$0.41 | $150.4M est $143.9M | +1.2% |
| May 2, 2024 | −$0.36 est −$0.42 | $138.5M est $135.8M | +16.0% |
| Feb 22, 2024 | −$0.45 est −$0.52 | — | −2.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
NovoCure stock forecast and analyst price targets
Analysts’ average 12-month price target for NovoCure is $26.86, +82.5% from the last close, from 3 firms rating the stock in the last 90 days.
$26.86consensus 12-month target, +82.5% from the last close
Now $14.72Avg $26.86
Low $20High $52
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Jul 24 | H.C. Wainwright | $52 | +253.3% |
| Jul 24 | Wedbush | $20 | +35.9% |
| Jul 24 | Piper Sandler | $29 | +97.0% |
+7.5%average 20-day move after past Accumulation readings
−4.6%average move over the next 20 trading days in the last 5 years
±4.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
NovoCure seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, NovoCure averaged −4.6% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.8% | 3 of 5 |
| Next 10 trading days | −1.4% | 3 of 5 |
| Next 15 trading days | −3.1% | 1 of 5 |
| Next 20 trading days | −4.6% | 1 of 5 |
| Next 30 trading days | −6.7% | 1 of 5 |
For scale, NVCR’s typical 20-trading-day move in either direction is about 11.9%.
NovoCure market cap and key statistics
NovoCure’s market cap is $1.71B and revenue of $699.2M over the last twelve months.
Valuation
- Market cap
- $1.71B
- Forward P/E
- 909.1
- EPS, TTM
- −$1.30
- Gekko Fair Value
- $20.41
Trading
- Volume
- 781,976
- Avg volume, 20 days
- 1.34M
- 52-week high
- $21.45
- 52-week low
- $9.82
- Shares outstanding
- 116.4M
Financials
- Revenue, TTM
- $699.2M
- Profit margin
- -21.2%
- Return on equity
- -43.2%
- Quarterly earnings growth, YoY
- −6.0%
Risk and income
- Beta
- 0.99
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±11.9%
NovoCure stock news this week
Coverage of NovoCure this week reads neutral: 2 positive, 1 neutral and 2 negative headlines.
- Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)Defense World, Oct 12
- Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)Defense World, Oct 11
- Did Japan Pancreatic Cancer Approval Just Shift NovoCure's (NVCR) Investment Narrative?Simply Wall Street, Oct 10
- Insiders At NovoCure Sold US$3.3m In Stock, Alluding To Potential WeaknessMoomoo, Oct 9
- Novocure received Japan approval. Novocure stock fell 4.51 percentAD HOC NEWS, Oct 8
- NovoCure (NVDA) Could Be 69% Undervalued After Japan Pancreatic Cancer ApprovalSimply Wall Street, Oct 7
NovoCure peers
NovoCure’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
NovoCure stock FAQ
What is NovoCure’s market cap?
NovoCure’s market cap is $1.71B at the Oct 12, 2026 close of $14.72, with 116.4M shares outstanding.
What is the NovoCure stock forecast?
The consensus analyst 12-month price target for NovoCure is $26.86, +82.5% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is NovoCure stock overvalued or undervalued?
On Gekko’s estimate NovoCure is undervalued: the Oct 12, 2026 close of $14.72 is 27.9% below Gekko Fair Value of $20.41. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does NovoCure report earnings next?
NovoCure is expected to report on Oct 29, 2026, before the market opens (17 days away). Analysts expect earnings of −$0.23 per share on revenue of $182.3M. NovoCure beat the earnings estimate in 7 of its last 8 reports, moving 7.3% on average across the report.
What is NovoCure’s 52-week high and low?
NovoCure’s 52-week high is $21.45 and its 52-week low is $9.82; it closed at $14.72 on Oct 12, 2026, +2.7% over the past year. Over the last five years the shares peaked at $124.35 on Oct 22, 2021.
Is NovoCure stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See NovoCure the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.